Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

New treatments for mitochondrial disease—no time to drop our standards

Open access
Pfeffer, Gerald, Horvath, Rita, Klopstock, Thomas, Mootha, Vamsi K., Suomalainen, Anu, Koene, Saskia, Hirano, Michio, Zeviani, Massimo, Bindoff, Laurence A., Yu-Wai-Man, Patrick, Hanna, Michael, Carelli, Valerio, McFarland, Robert, Majamaa, Kari, Turnbull, Douglas M., Smeitink, Jan, Chinnery, Patrick F. · 2013 · Nature Reviews Neurology

Abstract

Mitochondrial dysfunction is a common cause of inherited multisystem disease that often involves the nervous system. Despite major advances in our understanding of the pathophysiology of mitochondrial diseases, clinical management of these conditions remains largely supportive. Using a systematic approach, we identified 1,039 publications on treatments for mitochondrial diseases, only 35 of which included observations on more than five patients. Reports of a positive outcome on the basis of a biomarker of unproven clinical significance were more common in nonrandomized and nonblinded studies, suggesting a publication bias toward positive but poorly executed studies. Although trial design is improving, there is a critical need to develop new biomarkers of mitochondrial disease. In this Perspectives article, we make recommendations for the design of future treatment trials in mitochondrial diseases. Patients and physicians should no longer rely on potentially biased data, with the associated costs and risks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrneurol.2013.129

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 167

Metadata

Authors
Pfeffer, G., Horvath, R., Klopstock, T., Mootha, V. K., Suomalainen, A., Koene, S., Hirano, M., Zeviani, M., Bindoff, L. A., Yu-Wai-Man, P., Hanna, M., Carelli, V., McFarland, R., Majamaa, K., Turnbull, D. M., Smeitink, J., & Chinnery, P. F.
Venue
Nature Reviews Neurology
Published
2013-07-02
Volume
9
Issue
8
Pages
474-481
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W2137135936
Cited by
167
References
4
FWCI
1.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New treatments for mitochondrial disease—no time to drop our standards. https://app.cochat.ai/papers/10.1038/nrneurol.2013.129
The paper
Pfeffer, G., Horvath, R., Klopstock, T., Mootha, V. K., Suomalainen, A., Koene, S., Hirano, M., Zeviani, M., Bindoff, L. A., Yu-Wai-Man, P., Hanna, M., Carelli, V., McFarland, R., Majamaa, K., Turnbull, D. M., Smeitink, J., & Chinnery, P. F. (2013). New treatments for mitochondrial disease—no time to drop our standards. Nature Reviews Neurology. https://doi.org/10.1038/nrneurol.2013.129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.